{"id":"https://openalex.org/W4292219829","doi":"https://doi.org/10.1111/bcp.15498","title":"Model\u2010based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma","display_name":"Model\u2010based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma","publication_year":2022,"publication_date":"2022-08-18","ids":{"openalex":"https://openalex.org/W4292219829","doi":"https://doi.org/10.1111/bcp.15498","pmid":"https://pubmed.ncbi.nlm.nih.gov/35981078"},"language":"en","primary_location":{"id":"doi:10.1111/bcp.15498","doi":"https://doi.org/10.1111/bcp.15498","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcp.15498","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101710263","display_name":"Yiming Cheng","orcid":"https://orcid.org/0000-0001-5428-9418","observed_orcids":["https://orcid.org/0000-0001-5428-9418"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yiming Cheng","raw_affiliation_strings":["Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":"https://orcid.org/0000-0001-5428-9418","affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102333017","display_name":"Yongjun Xue","orcid":"https://orcid.org/0009-0002-2820-7006","observed_orcids":["https://orcid.org/0009-0002-2820-7006"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yongjun Xue","raw_affiliation_strings":["Non\u2010Clinical Research & Development Bristol Myers Squibb  Princeton NJ USA","Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Non\u2010Clinical Research & Development Bristol Myers Squibb  Princeton NJ USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Non-Clinical Research & Development, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100432074","display_name":"Lu Chen","orcid":"https://orcid.org/0000-0002-1250-3778","observed_orcids":["https://orcid.org/0000-0002-1250-3778"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lu Chen","raw_affiliation_strings":["Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034501696","display_name":"Mark Masin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I47396830","display_name":"Bristol-Myers Squibb (Switzerland)","ror":"https://ror.org/02xqc6638","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I47396830"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Mark Masin","raw_affiliation_strings":["Global Drug Development, Celgene International S\u00e0rl a Bristol\u2010Myers Squibb Company  Boudry Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development, Celgene International S\u00e0rl a Bristol\u2010Myers Squibb Company  Boudry Switzerland","institution_ids":["https://openalex.org/I47396830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089774924","display_name":"Paulo Maciag","orcid":"https://orcid.org/0000-0003-1172-9772","observed_orcids":["https://orcid.org/0000-0003-1172-9772"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paulo Maciag","raw_affiliation_strings":["Global Drug Development Bristol Myers Squibb  Princeton NJ USA","Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development Bristol Myers Squibb  Princeton NJ USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Global Drug Development, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000535220","display_name":"Teresa Peluso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I47396830","display_name":"Bristol-Myers Squibb (Switzerland)","ror":"https://ror.org/02xqc6638","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I47396830"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Teresa Peluso","raw_affiliation_strings":["Global Drug Development, Celgene International S\u00e0rl a Bristol\u2010Myers Squibb Company  Boudry Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Drug Development, Celgene International S\u00e0rl a Bristol\u2010Myers Squibb Company  Boudry Switzerland","institution_ids":["https://openalex.org/I47396830"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109036817","display_name":"Simon Yuji Zhou","orcid":"https://orcid.org/0000-0003-4688-3307","observed_orcids":["https://orcid.org/0000-0003-4688-3307"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Simon Zhou","raw_affiliation_strings":["Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100711754","display_name":"Yan Li","orcid":"https://orcid.org/0000-0001-7609-2683","observed_orcids":["https://orcid.org/0000-0001-7609-2683"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Yan Li","raw_affiliation_strings":["Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics Bristol Myers Squibb  Princeton NJ USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5100711754"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":2.0017,"has_fulltext":false,"cited_by_count":8,"citation_normalized_percentile":{"value":0.85397359,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":97},"biblio":{"volume":"89","issue":"1","first_page":"316","last_page":"329"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.48899999260902405,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.48899999260902405,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.3978999853134155,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.04390000179409981,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/iberdomide","display_name":"iberdomide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.921999990940094},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9599999785423279},{"id":"https://openalex.org/keywords/covariate-effects","display_name":"covariate effects","score":0.5260000228881836},{"id":"https://openalex.org/keywords/liver-dysfunction","display_name":"liver dysfunction","score":0.6779999732971191},{"id":"https://openalex.org/keywords/renal-dysfunction","display_name":"renal dysfunction","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6759999990463257},{"id":"https://openalex.org/keywords/two-compartment-model","display_name":"two-compartment model","score":0.6679999828338623}],"concepts":[{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.8163979649543762},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7324991226196289},{"id":"https://openalex.org/C2777501473","wikidata":"https://www.wikidata.org/wiki/Q1796666","display_name":"Body surface area","level":2,"score":0.7093269228935242},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6894893646240234},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.6095234751701355},{"id":"https://openalex.org/C139254425","wikidata":"https://www.wikidata.org/wiki/Q1332167","display_name":"Volume of distribution","level":3,"score":0.6057366132736206},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.5677549839019775},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4729219079017639},{"id":"https://openalex.org/C119043178","wikidata":"https://www.wikidata.org/wiki/Q320723","display_name":"Covariate","level":2,"score":0.46005815267562866},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.45572465658187866},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42445042729377747},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3498346209526062},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.0},{"id":"https://openalex.org/C105795698","wikidata":"https://www.wikidata.org/wiki/Q12483","display_name":"Statistics","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D009101","descriptor_name":"Multiple Myeloma","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D010797","descriptor_name":"Phthalimides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010881","descriptor_name":"Piperidones","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015992","descriptor_name":"Body Mass Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015992","descriptor_name":"Body Mass Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015992","descriptor_name":"Body Mass Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/bcp.15498","doi":"https://doi.org/10.1111/bcp.15498","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcp.15498","pdf_url":null,"source":{"id":"https://openalex.org/S13842274","display_name":"British Journal of Clinical Pharmacology","issn_l":"0306-5251","issn":["0306-5251","1365-2125"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-2","ki-jl-2","medline","norway-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:35981078","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35981078","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British journal of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5299999713897705,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1887243203","https://openalex.org/W1993558831","https://openalex.org/W2021315742","https://openalex.org/W2082039020","https://openalex.org/W2127547864","https://openalex.org/W2604153678","https://openalex.org/W2606131188","https://openalex.org/W2738198749","https://openalex.org/W2955507058","https://openalex.org/W2988470278","https://openalex.org/W3087909260","https://openalex.org/W3088719570","https://openalex.org/W3089045575","https://openalex.org/W3095352143","https://openalex.org/W3136441044","https://openalex.org/W3138604854","https://openalex.org/W3157905247","https://openalex.org/W3165120182","https://openalex.org/W3186271152","https://openalex.org/W3202213124"],"related_works":["https://openalex.org/W2985746494","https://openalex.org/W4206042385","https://openalex.org/W2511384863","https://openalex.org/W2096089271","https://openalex.org/W2923628599","https://openalex.org/W2014100433","https://openalex.org/W1571987355","https://openalex.org/W4388202839","https://openalex.org/W4388461648","https://openalex.org/W2115433709"],"abstract_inverted_index":{"AIMS:":[0],"A":[1,99],"parent-metabolite":[2],"population":[3,216],"pharmacokinetic":[4],"(popPK)":[5],"model":[6,70,93,112,204],"of":[7,20,37,85,136,173],"iberdomide":[8,38,86,220],"and":[9,17,22,49,53,97,133,150,155,184,193,199,217],"its":[10],"pharmacologically":[11],"active":[12],"metabolite":[13,111,176],"(M12)":[14,168],"was":[15,28,64,103,125,180],"developed":[16],"the":[18,68,107,114,139,171,210],"influence":[19],"demographic":[21],"disease-related":[23],"covariates":[24,163],"on":[25,31,72,130,164],"popPK":[26,69],"parameters":[27],"assessed":[29],"based":[30,71],"data":[32,73],"from":[33,74],"3":[34,78],"clinical":[35,79],"studies":[36],"(dose":[39],"range,":[40],"0.1-6":[41],"mg)":[42],"in":[43],"healthy":[44,123,151],"subjects":[45,76],"(n":[46,57],"=":[47],"81)":[48],"patients":[50,121,146],"with":[51,90,94,113,147,191],"relapsed":[52],"refractory":[54],"multiple":[55,148],"myeloma":[56,120,149],"245).":[58],"METHODS:":[59],"Nonlinear":[60],"mixed":[61],"effects":[62],"modelling":[63],"used":[65,104,207],"to":[66,105,177,208],"develop":[67],"326":[75],"across":[77,182],"studies.":[80],"RESULTS:":[81],"The":[82,175,203],"pharmacokinetics":[83],"(PK)":[84],"were":[87,157],"adequately":[88],"described":[89],"a":[91,126],"2-compartment":[92],"first-order":[95,100],"absorption":[96],"elimination.":[98],"conversion":[101],"rate":[102],"link":[106],"1-compartment":[108],"linear":[109],"elimination":[110],"parent":[115,178],"model.":[116],"Subject":[117],"type":[118],"(multiple":[119],"vs.":[122],"subject)":[124],"statistically":[127,158],"significant":[128],"covariate":[129],"apparent":[131,134,165],"clearance":[132],"volume":[135],"distribution":[137],"for":[138,213],"central":[140],"compartment,":[141],"suggesting":[142],"different":[143],"PK":[144,169,172],"between":[145],"subjects.":[152],"Aspartate":[153],"aminotransferase":[154],"sex":[156],"but":[159],"not":[160],"clinically":[161],"relevant":[162],"clearance.":[166],"Metabolite":[167],"tracked":[170],"iberdomide.":[174],"ratio":[179],"consistent":[181],"doses":[183],"combinations.":[185],"CONCLUSION:":[186],"]),":[187],"combination":[188,190],"(in":[189],"dexamethasone":[192],"daratumumab),":[194],"mild":[195,198],"hepatic,":[196],"or":[197],"moderate":[200],"renal":[201],"impairments.":[202],"can":[205],"be":[206],"guide":[209],"dosing":[211],"strategy":[212],"special":[214],"patient":[215],"inform":[218],"future":[219],"study":[221],"design.":[222]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2025-10-10T00:00:00"}